As the year comes to a close, I’ve taken a moment to reflect on what has been one of Elixir’s most meaningful chapters so far. We move fast, and it’s easy to overlook how far we’ve come, but I feel incredibly proud of this team and everything we’ve achieved together.

2025 was a year of strong commercial growth for Elixir. We broadened our global footprint, strengthened relationships with long-standing customers, and saw increasing adoption across our product lines - reflecting both the maturity of our platforms and the trust the scientific community places in us.

Scientific organisations continue to face pressure to accelerate discovery while managing complex data and operational demands. This is exactly where Elixir is focused. Across global R&D, our products continue to make a measurable impact, with iTraX Analytical Chemistry featured at leading scientific conferences through customer-led presentations on how it is helping streamline real workflows.

From a product perspective, we made meaningful advances. iTraX saw improvements in interoperability, user experience and platform scalability. Our Chemistry platform - the first scientific tracking solution of its kind and now entering its fourteenth year - continued to evolve with enhancements that strengthen its position as a trusted, mature product. We also saw growing uptake in Study Management as organisations look for more integrated, data-driven scientific operations.

We continued to expand our commercial capabilities and earned trust from customers who tell us that Elixir now feels like part of their internal team - a compliment we never take for granted. We also deepened alignment with key technology partners to ensure iTraX fits seamlessly into the environments shaping modern R&D.

Looking ahead, we are increasing our capabilities in AI. A highlight this year was our invitation to PRISME, whose vision for the Software-Defined Lab aligns closely with ours. It reaffirmed our long-standing mission - creating more time for science so teams can explore, innovate and deliver life-changing medicines faster.

Above all, this year underscored the people, expertise and purpose that sit at the centre of Elixir’s success.

We move into 2026 with confidence and momentum - and there is so much more ahead.

Thank you to the entire Elixir team, our partners and the wider scientific community who continue to place their trust in us.

Here’s to the next chapter.

Paul

CEO, Elixir Software